SEC
VERV

Seven Eight Capital’s Verve Therapeutics VERV Stock Holding History

Seven Eight Capital’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,562
Closed -$287K – 838
2023
Q4 		$287K Buy
+20,562
New +$255K 0.03% 524

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Seven Eight Capital's VERV Position: Q1 2024 in Review

Seven Eight Capital sold out of Verve Therapeutics (VERV) in Q1 2024, closing a stake of 20,562 shares — an estimated $287K sold.

Seven Eight Capital first reported a position in VERV in Q4 2023 and held it in 1 quarter. The position peaked at $287K in Q4 2023. 163 funds tracked by Wall St. Rank hold VERV as of Q1 2024.

  • Seven Eight Capital reported no remaining Verve Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Seven Eight Capital sold 20,562 Verve Therapeutics shares in Q1 2024, an estimated $287K.
  • Seven Eight Capital first reported a position in Verve Therapeutics in Q4 2023 and held it in 1 quarter.
  • Seven Eight Capital's Verve Therapeutics position peaked at $287K in Q4 2023.
  • 163 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2024.

Based on Seven Eight Capital's 13F filing for Q1 2024, filed 13 May 2024.